SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

GODAVARI DRUGS

BSE: 530317 09 Sep 2025
Healthcare
₹ 84
Godavari Drugs Ltd. specializes in Pharmaceuticals within the Healthcare sector.

GODAVARI DRUGS - Share Price & Details

Market Cap
₹62.4
High /Low
146.0 / 79.0
Stock P/E
16.5
Book Value
₹57.6
Dividend Yield
0.0
ROCE
10.1
ROE
₹10.6
Face Value
10.0
PEG Ratio
-2.71
EVEBITDA
₹10.6
Debt
64.4
CMP / FCF
278.0
Debt to equity
₹1.48
NP Ann
4.38
High price all time
155.0
Piotroski score
₹5.0
Graham Number
80.7
No. Eq. Shares
0.75
Net CF
₹-0.25
Net profit
3.79
Price to book value
1.43
Interest Coverage
₹2.15
Low price all time
2.61
Industry PE
33.4
Reserves
₹35.8
Free Cash Flow
₹-8.80

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
FABINO ENTERPRISES LIMITEDNANANANA5.4691.0
Triochem Products Ltd.,NANANANA0
GODAVARI DRUGS LTD.NANANANA62.416.5
TRANSCHEM LTD.NANANANA58.212.8
VASUNDHARA RASAYANS LTDNANANANA56.814.4

Peer Comparison Chart


About GODAVARI DRUGS

Godavari Drugs Ltd., with Security Code 530317, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Godavari Drugs standalone net profit declines 36.20% in the June 2025 quarter

(14 Aug 2025)
Net profit of Godavari Drugs declined 36.20% to Rs 1.04 crore in the quarter ended June 2025 as against Rs 1.63 crore during the previous quarter ended June...
Read more →

Progrex Ventures reports standalone net loss of Rs 0.02 crore in the June 2025 quarter

(14 Aug 2025)
Net Loss of Progrex Ventures reported to Rs 0.02 crore in the quarter ended June 2025 as against net loss of Rs 0.01 crore during the previous quarter ended...
Read more →

U. Y. Fincorp standalone net profit rises 17.52% in the June 2025 quarter

(14 Aug 2025)
Net profit of U. Y. Fincorp rose 17.52% to Rs 5.97 crore in the quarter ended June 2025 as against Rs 5.08 crore during the previous quarter ended June 2024...
Read more →

Archit Organosys standalone net profit rises 101.98% in the June 2025 quarter

(14 Aug 2025)
Net profit of Archit Organosys rose 101.98% to Rs 2.04 crore in the quarter ended June 2025 as against Rs 1.01 crore during the previous quarter ended June...
Read more →

Godavari Drugs Reports Declining Financial Metrics, Signals Need for Strategic Reassessment

(14 Aug 2025)
Godavari Drugs has announced its financial results for the quarter ending June 2025, revealing declines in key metrics. The Profit After Tax for the past...
Read more →

Smallcap stock hits 5% upper circuit after receiving cancer treatment patent from Chinese authorities

(06 Aug 2025)
Godavari Biorefineries Ltd. announced that the China National Intellectual Property Administration (CNIPA) has granted it a patent for a cancer treatment.
Read more →

Company Updates